마이크로바이오틱스
Seoul, KR · 1 known investors
MicrobiotiX develops bacteriophage-based therapeutics targeting multi-drug resistant bacterial infections, including WHO/CDC priority pathogens such as Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, and E. coli. The company operates a phage discovery and development platform with a library of about 1,000 bacteriophages, in-silico modules, and GMP production facilities, and its lead pipeline MP101 has entered clinical trials with first-patient-in completed.
Investors · 1
Frequently asked questions
- What does 마이크로바이오틱스 do?
- MicrobiotiX develops bacteriophage-based therapeutics targeting multi-drug resistant bacterial infections, including WHO/CDC priority pathogens such as Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, and E. coli. The company operates a phage discovery and development platform with a library of about 1,000 bacteriophages, in-silico modules, and GMP production facilities, and its lead pipeline MP101 has entered clinical trials with first-patient-in completed.
- Who are 마이크로바이오틱스's investors?
- 마이크로바이오틱스's investors include Solidus Investment.
- Where is 마이크로바이오틱스 headquartered?
- 마이크로바이오틱스 is headquartered in Seoul, KR.